Using immune therapy and antibiotics to treat severe inflammation in older patients with sepsis and ARDS.
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients
This study is looking at a new way to help older adults with sepsis and severe breathing problems by using a mix of immune therapy and antibiotics, focusing on a special immune receptor that might help reduce harmful inflammation and improve their chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioprovar Corporation NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10300896 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating sepsis and acute respiratory distress syndrome (ARDS) in geriatric patients by combining immune therapy with antibiotics. The study focuses on the role of TREM1, a receptor involved in the immune response, and its splice variant TREM1-sv, which may help regulate excessive inflammation caused by bacterial infections. By targeting this pathway, the research aims to improve survival rates in older adults suffering from these life-threatening conditions. Patients will be monitored for their response to this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are geriatric patients diagnosed with sepsis or ARDS due to severe bacterial infections.
Not a fit: Patients who are not elderly or those without a diagnosis of sepsis or ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase survival rates for elderly patients suffering from sepsis and ARDS.
How similar studies have performed: Previous research has shown promising results in targeting the TREM1 pathway for reducing inflammation, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- Bioprovar Corporation — Houston, United States (Active)
Researchers
- Principal investigator: Roussel, Eugene — Bioprovar Corporation
- Study coordinator: Roussel, Eugene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.